Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Caris Life Sciences, OSUCC, National Cancer Center Japan, Phoenix Molecular Designs

NEW YORK – Caris Life Sciences said this week that it has added Ohio State University and the National Cancer Center Japan to its Caris Precision Oncology Alliance (POA).

As a POA member, Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCC – James) will collaborate with other alliance members on research into biomarker-driven cancer care.

Caris says that NCC Japan — the largest cancer research organization in Japan with 43 affiliated network locations — will "add significant diversity in the patient populations being studied for impactful precision oncology research." 

Caris' POA includes around 60 cancer centers and academic institutions, all of which have early access to Caris' genomic, transcriptomic, and proteomic profiling platform, Caris Molecular Intelligence, and the firm's extensive database. 

Phoenix Molecular Designs said this week that it has completed patient enrollment and dosing in its Phase I/Ib trial of the RSK inhibitor PMD-026 in metastatic triple-negative breast cancer. In the trial, the company also assessed whether RSK2 expression was tied to patient outcomes. Based on interim data, Phoenix found that patients with high RSK2 expression benefited more from the drug than patients with low expression. Specifically, median progression-free survival in RSK2-high patients was three times longer than in the RSK2-low group. Phoenix expects to release top-line data from the study in the second quarter of this year. Based on the safety profile of PMD-026, the company is beginning to explore combination trials in TNBC and hormone receptor-positive breast cancer. 

Spectrum Pharmaceuticals said this week that the US Food and Drug Administration has accepted a new drug application for poziotinib as a treatment for advanced non-small cell lung cancers harboring HER2 exon 20 insertion mutations. Henderson, Nevada-based Spectrum filed the application in late 2021 based on the results of the Phase II ZENITH20 study. The FDA is now reviewing the application and is expected to issue a decision in November 2022. According to Spectrum, the FDA told Spectrum that it will be important to have a confirmatory trial substantially enrolled at the time of approval, and has requested additional information regarding dosing.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.